Watch out Bris­tol My­ers, Mer­ck is right on your heels with more pos­i­tive Keytru­da da­ta to take to the FDA

Mer­ck an­nounced pos­i­tive Phase III re­sults to back yet an­oth­er in­di­ca­tion for cash cow Keytru­da — this time as a first-line esophageal can­cer treat­ment in com­bi­na­tion with chemother­a­py.

Keytru­da al­ready has the FDA OK as a sec­ond-line monother­a­py for PD-L1-pos­i­tive pa­tients with re­cur­rent lo­cal­ly ad­vanced or metasta­t­ic squa­mous cell car­ci­no­ma of the esoph­a­gus. But Mer­ck is still push­ing for first-line ap­proval as a ther­a­py for the dif­fi­cult-to-treat can­cer, and it met pri­ma­ry end­points in a Phase III tri­al.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN